{"id":"https://openalex.org/W2017395282","doi":"https://doi.org/10.1097/iae.0b013e318030a290","title":"INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY WITH PEGAPTANIB FOR ADVANCED VON HIPPEL-LINDAU DISEASE OF THE RETINA","display_name":"INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY WITH PEGAPTANIB FOR ADVANCED VON HIPPEL-LINDAU DISEASE OF THE RETINA","publication_year":2007,"publication_date":"2007-02-01","ids":{"openalex":"https://openalex.org/W2017395282","doi":"https://doi.org/10.1097/iae.0b013e318030a290","mag":"2017395282","pmid":"https://pubmed.ncbi.nlm.nih.gov/17290195"},"language":"en","primary_location":{"id":"doi:10.1097/iae.0b013e318030a290","doi":"https://doi.org/10.1097/iae.0b013e318030a290","is_oa":false,"landing_page_url":"https://doi.org/10.1097/iae.0b013e318030a290","pdf_url":null,"source":{"id":"https://openalex.org/S19572933","display_name":"Retina","issn_l":"0275-004X","issn":["0275-004X","1539-2864"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Retina","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032283332","display_name":"Sam S. Dahr","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210139686","display_name":"National Eye Institute","ror":"https://ror.org/03wkg3b53","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"SAM S. DAHR","raw_affiliation_strings":["Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA","Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210139686"]},{"raw_affiliation_string":"Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006863549","display_name":"Michael Cusick","orcid":"https://orcid.org/0009-0000-5480-5777","observed_orcids":["https://orcid.org/0009-0000-5480-5777","https://orcid.org/0000-0002-7177-7090"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210139686","display_name":"National Eye Institute","ror":"https://ror.org/03wkg3b53","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"MICHAEL CUSICK","raw_affiliation_strings":["Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035803158","display_name":"Hanna Rodriguez-Coleman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210139686","display_name":"National Eye Institute","ror":"https://ror.org/03wkg3b53","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"HANNA RODRIGUEZ-COLEMAN","raw_affiliation_strings":["Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072863451","display_name":"Sunil K. Srivastava","orcid":"https://orcid.org/0000-0002-0398-8806","observed_orcids":["https://orcid.org/0000-0002-0398-8806"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210139686","display_name":"National Eye Institute","ror":"https://ror.org/03wkg3b53","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"SUNIL K. SRIVASTAVA","raw_affiliation_strings":["Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009887285","display_name":"Darby J. S. Thompson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115849","display_name":"Emmes (United States)","ror":"https://ror.org/027fvqp63","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115849"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"DARBY J. THOMPSON","raw_affiliation_strings":["EMMES Corporation, Rockville, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMMES Corporation, Rockville, Maryland","institution_ids":["https://openalex.org/I4210115849"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107963543","display_name":"William Marston Linehan","orcid":"https://orcid.org/0000-0001-7983-3109","observed_orcids":["https://orcid.org/0000-0001-7983-3109"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W MARSTON LINEHAN","raw_affiliation_strings":["Urological Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Urological Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010240899","display_name":"Frederick L. Ferris","orcid":"https://orcid.org/0000-0002-4933-0639","observed_orcids":["https://orcid.org/0000-0002-4933-0639"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210139686","display_name":"National Eye Institute","ror":"https://ror.org/03wkg3b53","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"FREDERICK L. FERRIS","raw_affiliation_strings":["Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090802305","display_name":"Emily Y. Chew","orcid":"https://orcid.org/0000-0003-0999-9802","observed_orcids":["https://orcid.org/0000-0003-0999-9802"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210139686","display_name":"National Eye Institute","ror":"https://ror.org/03wkg3b53","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"EMILY Y. CHEW","raw_affiliation_strings":["Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210139686"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5006863549","https://openalex.org/A5010240899","https://openalex.org/A5032283332","https://openalex.org/A5035803158","https://openalex.org/A5072863451","https://openalex.org/A5090802305"],"corresponding_institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210139686"],"apc_list":null,"apc_paid":null,"fwci":5.3799,"has_fulltext":false,"cited_by_count":81,"citation_normalized_percentile":{"value":0.95180522,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"27","issue":"2","first_page":"150","last_page":"158"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9663000106811523,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9663000106811523,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11328","display_name":"Ocular Oncology and Treatments","score":0.01590000092983246,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.004100000020116568,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/von-hippel-lindau-disease","display_name":"von Hippel-Lindau disease","score":0.9190000295639038},{"id":"https://openalex.org/keywords/pegaptanib","display_name":"pegaptanib","score":0.8730000257492065},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.9490000009536743},{"id":"https://openalex.org/keywords/intravitreal-injection","display_name":"intravitreal injection","score":0.9660000205039978},{"id":"https://openalex.org/keywords/retinal-angioma","display_name":"retinal angioma","score":0.9309999942779541},{"id":"https://openalex.org/keywords/macular-thickness","display_name":"macular thickness","score":0.9229999780654907},{"id":"https://openalex.org/keywords/visual-acuity","display_name":"visual acuity","score":0.9049999713897705},{"id":"https://openalex.org/keywords/vascular-permeability","display_name":"vascular permeability","score":0.9200000166893005},{"id":"https://openalex.org/keywords/tractional-retinal-detachment","display_name":"tractional retinal detachment","score":0.7960000038146973},{"id":"https://openalex.org/keywords/ocular-hypotony","display_name":"hypotony","score":0.9079999923706055}],"concepts":[{"id":"https://openalex.org/C2777512022","wikidata":"https://www.wikidata.org/wiki/Q409935","display_name":"Pegaptanib","level":5,"score":0.936566948890686},{"id":"https://openalex.org/C2777093970","wikidata":"https://www.wikidata.org/wiki/Q169342","display_name":"Retina","level":2,"score":0.638056218624115},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.5479720234870911},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47434201836586},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4216025173664093},{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.21837997436523438},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.2149994969367981},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.21001487970352173},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19168415665626526},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.1702089011669159},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.05179017782211304}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005451","descriptor_name":"Fluorescein Angiography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006623","descriptor_name":"von Hippel-Lindau Disease","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D006623","descriptor_name":"von Hippel-Lindau Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007267","descriptor_name":"Injections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014792","descriptor_name":"Visual Acuity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014822","descriptor_name":"Vitreous Body","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018324","descriptor_name":"Hemangioma, Capillary","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D018324","descriptor_name":"Hemangioma, Capillary","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019572","descriptor_name":"Retinal Neoplasms","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D019572","descriptor_name":"Retinal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D041623","descriptor_name":"Tomography, Optical Coherence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D052157","descriptor_name":"Aptamers, Nucleotide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D052157","descriptor_name":"Aptamers, Nucleotide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/iae.0b013e318030a290","doi":"https://doi.org/10.1097/iae.0b013e318030a290","is_oa":false,"landing_page_url":"https://doi.org/10.1097/iae.0b013e318030a290","pdf_url":null,"source":{"id":"https://openalex.org/S19572933","display_name":"Retina","issn_l":"0275-004X","issn":["0275-004X","1539-2864"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Retina","raw_type":"journal-article"},{"id":"pmid:17290195","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17290195","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Retina (Philadelphia, Pa.)","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G424296001","display_name":null,"funder_award_id":"Z99 EY999999","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G9000858652","display_name":"Medical Retina Fellowship","funder_award_id":"ZIEEY000487","funder_id":"https://openalex.org/F4320337350","funder_display_name":"National Eye Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337350","display_name":"National Eye Institute","ror":"https://ror.org/03wkg3b53"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W1593445655","https://openalex.org/W1749022239","https://openalex.org/W1802218256","https://openalex.org/W1910627688","https://openalex.org/W1988651185","https://openalex.org/W1989126616","https://openalex.org/W1992257311","https://openalex.org/W2024307723","https://openalex.org/W2028160721","https://openalex.org/W2029799544","https://openalex.org/W2030397858","https://openalex.org/W2068555261","https://openalex.org/W2090789862","https://openalex.org/W2091534585","https://openalex.org/W2093776019","https://openalex.org/W2094857036","https://openalex.org/W2098582960","https://openalex.org/W2114112168","https://openalex.org/W2117962595","https://openalex.org/W2128073997","https://openalex.org/W2134955443","https://openalex.org/W2163459967","https://openalex.org/W2164569818","https://openalex.org/W2165865627","https://openalex.org/W2415062471","https://openalex.org/W2551569844","https://openalex.org/W2612281319","https://openalex.org/W2727557826","https://openalex.org/W3021359737","https://openalex.org/W3023174345"],"related_works":["https://openalex.org/W3200199880","https://openalex.org/W959688347","https://openalex.org/W2400487552","https://openalex.org/W1189479858","https://openalex.org/W2871498","https://openalex.org/W2040219306","https://openalex.org/W2429542771","https://openalex.org/W7099379521","https://openalex.org/W2150990488","https://openalex.org/W4307425106"],"abstract_inverted_index":{"OBJECTIVE:":[0],"This":[1,39,245],"pilot":[2,47,274],"study":[3,40,48,83],"was":[4,41,84,177,257],"designed":[5],"to":[6,33,189,250],"provide":[7],"preliminary":[8],"data":[9],"concerning":[10],"the":[11,76,125,184,199,264,267],"safety":[12],"and":[13,114,129,144,193,233],"efficacy":[14],"of":[15,49,52,63,81,87,121,127,132,156,165,224,261,266],"pegylated":[16],"anti-vascular":[17],"endothelial":[18],"growth":[19],"factor":[20],"(VEGF)":[21],"therapy,":[22],"pegaptanib,":[23],"for":[24,61],"patients":[25,67,123,136,159,187,195,240],"with":[26,68,241],"juxtapapillary":[27],"or":[28,89,174],"large":[29],"peripheral":[30],"angiomas":[31,270],"secondary":[32],"von":[34],"Hippel-Lindau":[35],"(VHL)":[36],"disease.":[37],"METHODS:":[38],"an":[42],"open":[43],"label,":[44],"nonrandomized,":[45],"prospective,":[46],"intravitreal":[50],"injections":[51,223],"pegaptanib":[53],"(3":[54,92],"mg/100":[55],"microL),":[56],"given":[57],"every":[58],"6":[59,64],"weeks":[60],"minimum":[62],"injections.":[65],"Five":[66],"severe":[69],"ocular":[70],"VHL":[71,243],"lesions":[72],"were":[73],"enrolled":[74],"in":[75,94,105,116,140,146,162,171,179,183,218,238,253,271],"study.":[77,275],"The":[78],"primary":[79,268],"outcome":[80],"this":[82,272],"a":[85,206,251],"change":[86,170],">":[88],"=15":[90],"letters":[91],"lines)":[93],"best-corrected":[95],"visual":[96,163],"acuity":[97,164],"by":[98,110,151],"1":[99,130],"year.":[100],"Secondary":[101],"outcomes":[102],"included":[103,214],"changes":[104,115],"macular":[106],"thickness,":[107],"as":[108],"determined":[109],"optical":[111,152],"coherence":[112,153],"tomography,":[113],"fluorescein":[117,172],"leakage.":[118],"RESULTS:":[119],"Two":[120],"five":[122],"completed":[124],"course":[126],"treatment":[128,201,262],"year":[131],"follow-up.":[133],"These":[134],"two":[135,158,219],"had":[137,160],"progressive":[138],"decrease":[139,229],"retinal":[141,148,208,230,235,269],"hard":[142,236],"exudate":[143],"reduction":[145,252],"central":[147],"thickness":[149],"measured":[150],"tomography.":[154],"One":[155,203],"these":[157,194],"improvement":[161],"3":[166],"lines.":[167],"No":[168],"significant":[169],"leakage":[173],"tumor":[175],"size":[176,265],"detected":[178],"either":[180],"patient.":[181],"Lesions":[182],"other":[185],"three":[186],"continued":[188],"progress":[190],"despite":[191],"treatment,":[192],"did":[196],"not":[197],"complete":[198],"entire":[200],"course.":[202],"patient":[204],"developed":[205],"tractional":[207],"detachment.":[209],"Additional":[210],"serious":[211],"adverse":[212],"events":[213],"transient":[215],"postinjection":[216],"hypotony":[217],"eyes.":[220],"CONCLUSIONS:":[221],"Intravitreal":[222],"anti-VEGF":[225],"therapy":[226],"(pegaptanib)":[227],"may":[228,247],"thickening":[231],"minimally":[232],"reduce":[234],"exudates":[237],"some":[239],"advanced":[242],"angiomas.":[244],"finding":[246],"be":[248],"related":[249],"vasopermeability,":[254],"because":[255],"there":[256],"no":[258],"apparent":[259],"effect":[260],"on":[263],"small":[273]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}